From: Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review
Outcome measures | Dietary supplement | Cardiovascular drug(s) | Conclusion effect estimate | Applicability |
---|---|---|---|---|
Lipid profile | Co-Q10 (200 mg/day) | Fenofibrate | No difference for HDL-C (one study): MD,1.55 mg/dL (95% CI −6.78, 3.68) | Mean age: |
 |  |  |  | 53 years |
 |  |  |  | Mixed gender |
 |  |  |  | High CHD risk |
 |  |  |  | 12 weeks treatment |
Lipid profile | Garlic (4 g/day) | Nitrates | In favor of combination | Unknown age, gender |
 |  |  | HDL-C (one study): MD, 8.40 mg/dL (95% CI 1.91, 14.89) | High CHD risk |
 |  |  |  | 12 weeks treatment |
Lipid profile | Omega-3-fish oil (3.6 g/day omega-3 to 9.2 g/day fish oil) | Statins | In favor of combination | Mean age: 45 to 63 years |
 |  |  | TG (two studies pooled): MD, -74.95 mg/dL (95% CI −95.80, -54.10)a | Mixed CHD risk |
 |  |  | No difference between combination and CV drug alone | Mixed gender |
 |  |  | HDL-C (six studies pooled): MD, 2.26 mg/dL (95% CI −1.8, 6.3) | Up to 25 weeks treatment |
 |  |  | LDL-C (five studies pooled): MD, 1.3 mg/dL (95% CI −3.6, 6.2) |  |
 |  |  | Achieving LDL-C targets: RR 0.93 (95% CI 0.84, 1.03) |  |
 |  |  | Achieving HDL-C targets (one study): and 1.00 (95% CI 0.90, 1.10) |  |
Lipid profile | Omega-3-fish oil (1.8 g/day)+ | Calcium channel blockers + aspirin | In favor of combination | Mean age: 57 y; |
 |  |  | TG (two studies not pooled): MD −81.00 mg/dL (95% CI −125.30, -36.70) and MD −54.00 mg/dL (95% CI −94.1, -13.90) | 85% men |
 |  |  |  | High CHD risk |
 |  |  |  | Up to 6 weeks treatment |
Lipid profile | Omega-3-fish oil (3.2 g/day) | Calcium channel blockers + aspirin, or dipyridamole | In favor of CV drug alone | Mean age: 56 y; |
 |  |  | LDL-C (one study): MD 21.00 mg/dL (95% CI 3.30, 38.70) | 100% men |
 |  |  | In favor of combination | High CHD risk |
 |  |  | TG (one study): MD −81.0 mg/dL (95% CI -125.30, -36.70) |  |
 |  |  |  | Up to 12 weeks treatment |
Lipid profile | Vitamin E (900 mg/day) | Nifedipine | In favor of combination | Elderly; mixed gender |
 |  |  | LDL-C (one study): MD −39.83 mg/dL (95% CI −71.29, -8.37) | High CHD risk |
 |  |  |  | 12 weeks treatment |
 |  |  | In favor of combination |  |
 |  |  | TG (one study): MD, -23.91 mg/dL (95% CI -35.89, -11.93) |  |
Blood pressure | Omega-3-fish oil (2 g/day)+ | Statins | In favor of combination | Mean age: 44 to 53 y; mixed gender |
 |  |  | Systolic blood pressure (one study): MD, -8.50 mmHg (95% CI -16.3, -0.66) | Mixed CHD risk |
 |  |  |  | 5 weeks treatment |
 |  |  | Systolic blood pressure (one study): median change from baseline −5.0 versus + 0.3 mmHg |  |
 |  |  | No difference between combination and CV drug alone |  |
 |  |  | Diastolic blood pressure (one study): MD, 0.20 mmHg (95% CI -4.76, 5.16) |  |
 | Omega-3-fish oil (4 g/day fish oil)+ | Statins | Diastolic blood pressure (one study): Median reductions from baseline -3.30 versus −1.80 to | Mean age: 58 y; Mixed gender |
 |  |  |  | Unclear CHD risk |
 |  |  |  | 6 weeks treatment |